VERU | tickerfilter.com

Fundamental analysis

12%

Profitability 8%

Dept financing 19%

Liquidity 75%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-2.87%

1 Month

-15.17%

3 Months

-19.02%

6 Months

-21.45%

1 Year

-12.43%

2 Year

-87.56%

Key data

Stock price

$0.69

P/E Ratio

-2.99

DAY RANGE

$0.63 - $0.67

EPS

-$0.33

52 WEEK RANGE

$0.38 - $1.92

52 WEEK CHANGE

-$17.15

MARKET CAP

119.801 M

YIELD

N/A

SHARES OUTSTANDING

146.384 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

12/06/2024

BETA

1.65

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,469,015

AVERAGE 30 VOLUME

$1,146,168

Company detail

CEO: Mitchell S. Steiner
Region: US
Website: verupharma.com
Employees: 230
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Toilet Preparation Manufacturing
Sector: Manufacturing

Veru Inc. focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company was formerly known as The Female Health Company.

VERU - VERU INC.